MedTrace Logo

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

NCT05223582 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-12-08

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

Conditions

  • High-risk Prostate Cancer
  • Neoadjuvant Therapy

Interventions

DRUG

Abiraterone acetate

Patients would be treated with 1000mg abiraterone qd.

DRUG

Fluzoparib

Patients would be treated with 150mg fluzoparib bid.

DRUG

Prednisone

Patients would be treated with 5mg prednisone bid.

DRUG

Androgen deprivation therapy

Patients would get medical castration.

PROCEDURE

Radical Prostatectomy

Patients would get radical prostatectomy after the neoadjuvant treatment.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05223582 on ClinicalTrials.gov